12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACH-3102: Phase Ib data

A Phase Ib trial in 14 patients with HCV genotype 1a infection showed that a single dose of 300 mg ACH-3102 led to a mean maximum HCV RNA reduction from baseline of 3.93 log10 IU/mL vs. 0.78 log10 IU/mL for placebo. The mean maximum HCV RNA reduction for a single 50 mg dose...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >